Toxicity manifesting as cosmetic hair alterations during erlotinib treatment

Author： Kudo Kenichiro   Fujiwara Keiichi   Tsushima Mizuho   Mizuta Makoto   Matsuo Kiyoshi   Yonei Toshiro   Sato Toshio  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.1, 2011-01, pp. : 146-148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of multiple keratoacanthomas with erlotinib

By Reid David   Guitart Joan   Agulnik Mark   Lacouture Mario  

International Journal of Clinical Oncology, Vol. 15, Iss. 4, 2010-08 ,pp. : 413-415

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib

By Robinson Dean M.   Keating Gillian M.   Perry Caroline M.  

American Journal of Cancer, Vol. 4, Iss. 4, 2005-01 ,pp. : 247-252

Adis International

Access to resources Recommend Favorite

Cosmetic Outcome and Breast Morbidity in Breast-Conserving Treatment

By Johansen Jørgen   Overgaard Jens   Rose Carsten   Engelholm Svend Aage   Gadeberg Carl C.   Kjaer Mogens   Kamby Claus   Juul-Christensen Jens   Blichert-Toft Mogens   Overgaard Marie  

Acta Oncologica, Vol. 41, Iss. 4, 2002-06 ,pp. : 369-380

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo   Cappuzzo Federico  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer

By Welch Stephen A   Moore Malcolm J  

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 247-254

Future Medicine

Access to resources Recommend Favorite